Aim Fever （body temperature,BT>37.5℃） was a commonly clinic scenery in acute ST-segment elevation myocardial infarction （STEMI） patients with primary percutaneous coronary intervention （PPCI）,while whether it has adverse effect on those patients with short-term prognosis was still unknown. Our study was mainly to observe its short-term adverse effect in STEMI patients with PPCI. Method With a retrospective analysis of 282 STEMI patients undergone PPCI,all patients’ BT peak in hospital was measured and divided into two groups,the fever group （BT>37.5℃） and the control group （BT≤37.5℃）. Compared two groups in the incidence of major adverse cardiac events （including cardiac death,non-fatal myocardial infarction and revascularization）. Results 106 patients were in the fever group with the percentage of 37.6% （106/282）. The white blood cells count,high-sensitivity C reactive protein and troponin I levels in the fever group were obviously higher than that in the control group,the frequency of myocardial infarction in past history and the left ventricular ejection fraction were much lower in the fever group,and there was no significant difference in hypertension,hyperlipidemia,angiography,diabetes mellitus and interventional treatment. The major adverse cardiac events at the sixth month were significantly higher in the fever group. Conclusion The fever is a predicted factor to poor short-term prognosis in STEMI patients with PPCI.